OGN
Organon & Co.
- Healthcare
- US companies in Drug Manufacturers - General (9)
- NYSE · USD
- Mkt cap $3.6bn
$13.74
as of 26 Oct 2026, 1% below its 52-week high
Screens as reasonably placed to keep growing its dividend, though with some cut-risk signals worth watching.
These scores are a resilience check on the dividend, not a recommendation to buy or sell. They are not financial advice.
- Trailing yield
- 0.58%Last 12 months of regular payments at today's price
- Forward yield
- 0.58%Each payment expected in the next 12 months, not the latest one doubled
- Earnings cover
- 11.6×Pays 9% of earnings
- Cash cover
- Over 20×Free cash flow over dividends paid
- 5y dividend growth
- Not availableCut in FY2025
- Next ex-dividend date
- Estimated20 Nov 2026Quarterly dividend of about $0.02
Compared with US companies in Drug Manufacturers - General (9)
- Trailing yield is lower than 7 of the 8 other US companies in Drug Manufacturers - General.
Quality
63
ModerateCapacity to keep growing the dividend
Risk
60
ModerateSignals of dividend-cut pressure
Trim
47
LowHow extended the valuation looks
Why Risk is 60
OGN against US companies in Drug Manufacturers - General (9)
Valuation against its own history
As of the last reported period (30 Jun 2026). P80 means the figure is higher than 80% of OGN’s past readings.
- P/E17.0×P100, poor for this measure
- Yield0.59%P5, poor for this measure
- Net debt / EBITDA5.65P82, poor for this measure
- ROIC7.9%P5, poor for this measure
Forecast your income with the OGN dividend calculator
Inspect surfaces history; it does not predict the future. Nothing here is financial advice or an instruction to buy or sell. Always do your own research. See the Terms of Service.